Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Heron Therapeutics, Inc. (HRTX) had Revenue of $32.81M for the most recently reported fiscal quarter, ending 2024-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2024-09-30

Income Statement Financials
Revenue	$32.81M
Net Income	$-4.85M
Cost of Goods Sold	$9.46M
Gross Profit	$23.35M
Operating Expenses	$37.27M
Operating Income	$-4.46M
Non-Operating Income/Expense	$-0.39M
Pre-Tax Income	$-4.85M
Normalized Pre-Tax Income	$-4.85M
Income after Taxes	$-4.85M
Income from Continuous Operations	$-4.85M
Consolidated Net Income/Loss	$-4.85M
Normalized Income after Taxes	$-4.85M
EBIT	$-4.46M
EBITDA	$-4.04M
Weighted-Average Shares Outstanding (Basic)	152.83M
Weighted-Average Shares Outstanding (Diluted)	152.83M
Earnings per Share (EPS) (Basic)	$-0.03
Earnings per Share (EPS) (Diluted)	$-0.03
Balance Sheet Financials
Current Assets	$195.19M
Property, Plant, and Equipment	$15.41M
Long-Term Assets	$25.59M
Total Assets	$220.78M
Current Liabilities	$85.54M
Long-Term Debt	$174.47M
Long-Term Liabilities	$175.24M
Total Liabilities	$260.78M
Common Equity	$-40.01M
Tangible Shareholders Equity	$-40.01M
Shareholders Equity	$-40.01M
Common Shares Outstanding	151.70M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-10.75M
Cash Flow from Investing Activities	$7.30M
Cash Flow from Financial Activities	$0.52M
Beginning Cash	$28.68M
End Cash	$25.74M
Increase/Decrease in Cash	$-2.94M
Stock-Based Compensation	$10.67M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.28
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.30
Debt to Equity Ratio	-4.36
Gross Margin	71.17%
Operating Margin	-13.59%
EBIT Margin	-13.59%
EBITDA Margin	--
Pre-Tax Profit Margin	-14.78%
Profit Margin	-14.78%
Free Cash Flow	$-11.82M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.21
Receiveable Turnover	0.49
Days Sales in Receivables	183.89
Return on Equity	12.12%
Return on Tangible Equity	12.12%
Return on Assets	-2.20%
Return on Investments	-3.61%
Book Value Per Share	$-0.26
Free Cash Flow per Share	$-0.08
Operating Cash Flow per Share	$-0.07

Data from Zacks Investment Research, Inc.